Applying nanomedicine in maladaptive inflammation and angiogenesis

Amr Alaarg, Carlos Pérez-Medina, Josbert M. Metselaar, Matthias Nahrendorf, Zahi A. Fayad, Gert Storm, Willem J.M. Mulder*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

39 Citations (Scopus)
25 Downloads (Pure)


Inflammation and angiogenesis drive the development and progression of multiple devastating diseases such as atherosclerosis, cancer, rheumatoid arthritis, and inflammatory bowel disease. Though these diseases have very different phenotypic consequences, they possess several common pathophysiological features in which monocyte recruitment, macrophage polarization, and enhanced vascular permeability play critical roles. Thus, developing rational targeting strategies tailored to the different stages of the journey of monocytes, from bone marrow to local lesions, and their extravasation from the vasculature in diseased tissues will advance nanomedicine. The integration of in vivo imaging uniquely allows studying nanoparticle kinetics, accumulation, clearance, and biological activity, at levels ranging from subcellular to an entire organism, and will shed light on the fate of intravenously administered nanomedicines. We anticipate that convergence of nanomedicines, biomedical engineering, and life sciences will help to advance clinically relevant therapeutics and diagnostic agents for patients with chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)143-158
Number of pages16
JournalAdvanced drug delivery reviews
Publication statusPublished - 15 Sept 2017


  • Angiogenesis
  • Atherosclerosis
  • Cancer
  • Chronic inflammation
  • Immunomodulation
  • Macrophages
  • Molecular imaging
  • Monocytes
  • Nanomedicine
  • Targeted drug delivery
  • 2023 OA procedure


Dive into the research topics of 'Applying nanomedicine in maladaptive inflammation and angiogenesis'. Together they form a unique fingerprint.

Cite this